Get started
Author

Felicity K. Namayanja

Observed names: Felicity K Namayanja, Felicity Namayanja
ORCID: 0009-0006-9536-5732
Observed ORCID: 0009-0006-9536-5732
OpenAlex ID: A5117724297
Broadening the gates: Analysis of potentially modifiable study entry criteria in pancreatic and biliary tract cancer trials
2025 · Fen Saj, Felicity K. Namayanja, et al. · Cancer · 2
PDF
ERBB3 driver genomic alterations in intrahepatic cholangiocarcinoma: A genomic landscape and clinical outcome study.
2026 · Mridula Nadamuni, Quentin Kimana, et al. · Journal of Clinical Oncology · 1
Multimodal evaluation of metabolic dysfunction–associated steatotic liver disease (MASLD)–related biliary tract cancer (BTC) and immunotherapy outcomes.
2025 · Nakul Manish Shah, Quentin Kimana, et al. · Journal of Clinical Oncology · 1
Association of gut microbiota with therapy efficacy and prognosis in biliary tract cancer.
2025 · Fen Saj, Ashish Damania, et al. · Journal of Clinical Oncology · 1
PDF
Proteogenomic Profiling Identifies FGFR2b as a Prevalent Cell Surface Target in Intrahepatic Cholangiocarcinoma
2026 · Nakul M. Shah, Beatriz Alvarado-Hernandez, et al. · Clinical Cancer Research
Abstract 3075: FGFR2b is a highly prevalent and actionable cell surface target in intrahepatic cholangiocarcinoma
2026 · Nakul M. Shah, Beatriz Alvarado-Hernandez, et al. · Cancer Research
Safety and efficacy of liver-directed radiotherapy after chemoimmunotherapy for advanced cholangiocarcinoma: an early report from a large tertiary cancer center
2025 · Abdulmoiz Asif, Abdulmoid Asif, et al. · Journal of Gastrointestinal Oncology
Broadening the gates: Analysis of potentially modifiable screen failures in pancreatic and biliary tract cancer trials.
2025 · Fen Saj, Felicity K. Namayanja, et al. · Journal of Clinical Oncology
PDF
Works count: 8
Citation count: 5
H-index: 1
I10-index:
Year
Topic
Type